Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience
This study found a clinically meaningful OS benefit in M-PHP-treated patients with liver-dominant mUM, reaching nearly 2.5-year median OS with ≥3 M-PHP cycles administered. This finding supports the need to account for the institutional volume and experience with the M-PHP procedure in both clinical practice and research, and may provide an OS reference for estimating OS gains in the evolving therapeutic landscape for mUM patients.
Authors
- Martin Schneider (ORCID: https://orcid.org/0000-0001-8215-7359)
- K Welcker (ORCID: https://orcid.org/0000-0001-6381-1378)
- Jochen Hoedtke
- Hauke Weilert
- Roland Brüning (ORCID: https://orcid.org/0000-0001-5737-7042)
- Andreas H. Mahnken (ORCID: https://orcid.org/0000-0001-8077-9306)
- Axel Stang (ORCID: https://orcid.org/0000-0001-8715-3349)
- Cäcilia S. Reiner
Institutions
- Mammazentrum Hamburg (DE)
- St. Josef-Hospital (DE)
- Asklepios Klinik Barmbek (DE)
- Asklepios Kliniken Hamburg (DE)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-29
- DOI
- https://doi.org/10.3390/cancers17233834
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00